This content is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. RLS diagnosis requires clinical evaluation. Speak with a healthcare provider before starting iron supplementation or any medication for RLS โ€” iron levels require laboratory testing to guide dosing, and some RLS medications carry significant risks.

What Is Restless Legs Syndrome?

Restless Legs Syndrome (RLS), also called Willis-Ekbom disease, is a neurological sensorimotor disorder characterized by an irresistible urge to move the legs, typically accompanied by uncomfortable or unpleasant sensations in the legs. It affects approximately 5โ€“10% of the general adult population, making it one of the more common neurological conditions.

RLS is frequently under-recognized because patients struggle to describe the sensations accurately โ€” they're often not pain, but rather an uncomfortable internal sensation: crawling, creeping, pulling, throbbing, itching, or electric-like feelings deep within the legs. The key feature is that movement relieves these sensations temporarily.

Diagnostic Criteria

The International RLS Study Group (IRLSSG) defines RLS by five essential criteria, all of which must be present:

  1. Urge to move the legs, usually accompanied by or thought to be caused by uncomfortable and unpleasant sensations in the legs
  2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity โ€” such as lying down or sitting
  3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
  4. The urge to move or unpleasant sensations are worse in the evening or night than during the day, or only occur in the evening or night
  5. These features are not accounted for solely by another medical or behavioral condition (mimics include positional discomfort, leg cramps, peripheral neuropathy, habitual foot tapping)

The Iron-Dopamine Connection

Understanding RLS requires understanding the relationship between iron and dopamine. Iron is an essential cofactor for the production of dopamine โ€” specifically, it's required by tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. In the brain regions relevant to RLS (particularly the substantia nigra and striatum), iron deficiency leads to dopamine system dysfunction even when systemic iron levels appear normal.

This is the critical clinical implication: RLS patients may have normal hemoglobin and appear iron-replete by standard blood tests, but have low brain iron stores. The clinically relevant measure for RLS is serum ferritin (a marker of iron storage), not hemoglobin alone. Research suggests that:

  • Ferritin below 75 ฮผg/L is associated with significantly worse RLS symptoms
  • Ferritin below 50 ฮผg/L is a strong indication for iron supplementation in RLS patients
  • Iron supplementation raises ferritin and substantially reduces RLS severity in iron-deficient patients
  • Intravenous iron infusion (ferric carboxymaltose or low molecular weight iron dextran) is used for patients who don't tolerate oral iron or have severe deficiency
If you have RLS: Ask your doctor for a complete iron panel including serum ferritin, not just hemoglobin. This is the most important first diagnostic step and, if low ferritin is found, iron supplementation alone can resolve or significantly reduce symptoms without requiring other medications.

Genetics and Other Contributing Factors

RLS has a strong genetic component โ€” approximately 40โ€“60% of RLS cases are familial, inherited in an autosomal dominant pattern with variable penetrance. Multiple genetic loci have been identified. This explains why RLS can run strongly in families and why some people develop it without any identified secondary cause.

Secondary RLS (caused by or associated with another condition) accounts for approximately 20โ€“30% of cases. Common secondary causes include:

  • Iron deficiency (the most common reversible cause)
  • Pregnancy (RLS affects 20โ€“25% of pregnant women, particularly in the third trimester โ€” usually resolves after delivery)
  • End-stage renal disease (iron deficiency and uremic toxins)
  • Peripheral neuropathy (diabetes, vitamin B12 deficiency)
  • Parkinson's disease (shared dopaminergic pathways)
  • Multiple sclerosis

Medications That Trigger or Worsen RLS

Several commonly prescribed medications can induce or significantly worsen RLS. This is an underappreciated clinical issue โ€” patients may develop RLS after starting a new medication without connecting the two. Medications known to worsen RLS include:

  • Antihistamines: First-generation antihistamines (diphenhydramine โ€” Benadryl, Tylenol PM, ZzzQuil) are particularly problematic and frequently used as OTC sleep aids. Dopamine-blocking properties worsen RLS significantly. Second-generation antihistamines (loratadine, cetirizine) are less dopaminergic and less problematic.
  • Antidepressants (especially SSRIs and SNRIs): Most SSRIs and SNRIs worsen RLS in susceptible individuals. Bupropion (Wellbutrin) is an exception โ€” it has dopaminergic properties and may actually improve RLS.
  • Antipsychotics and dopamine-blocking antiemetics: Metoclopramide, prochlorperazine, promethazine โ€” commonly used for nausea โ€” block dopamine receptors and can precipitate or worsen RLS.
  • Lithium
  • Caffeine (worsens for many patients)
  • Alcohol (complex relationship โ€” may temporarily relieve but often worsens RLS)

Periodic Limb Movement Disorder (PLMD)

PLMD is a related but distinct condition where repetitive, stereotyped limb movements occur during sleep โ€” typically involving leg jerks every 20โ€“40 seconds. Unlike RLS, these movements occur during sleep and the patient is not aware of them (though they cause arousals from sleep). Partners often observe the movements. Approximately 80% of RLS patients also have PLMD, but PLMD can exist without RLS.

PLMD is diagnosed by polysomnography (sleep study), which captures the periodic limb movements and their associated sleep disruption. Treatment is similar to RLS โ€” dopaminergic medications, alpha-2-delta ligands, and iron supplementation if deficient.

Treatment Options

Non-Pharmacological (First Line for Mild RLS)

  • Iron supplementation: If ferritin is below 75 ฮผg/L, oral iron (ferrous sulfate 325 mg with vitamin C for absorption) or IV iron. This is first-line before any prescription medication.
  • Stretching: Regular leg stretching (calf stretches, hamstring stretches) can reduce symptoms, particularly before bed
  • Warm or cool compresses: Temperature application to legs reduces symptoms in some patients
  • Leg massage: Temporary relief through proprioceptive stimulation
  • Pneumatic compression devices: Graduated pressure leg wraps have evidence from small studies
  • Exercise: Moderate aerobic exercise reduces RLS severity; avoid vigorous exercise immediately before bed (can temporarily worsen symptoms)
  • Eliminating triggers: Caffeine, alcohol, offending medications (discuss with prescriber before stopping)
  • Hot bath before bed: Temporary symptom relief
  • Mental engagement: Active cognitive engagement (video games, puzzles) can reduce symptoms when they'd otherwise prevent sleep

Pharmacological Treatment

Alpha-2-Delta Ligands (Preferred First-Line Medication)

Gabapentin (Neurontin) and pregabalin (Lyrica) are now preferred first-line pharmacological treatments for RLS when non-pharmacological approaches and iron supplementation are insufficient. They work through calcium channel modulation and don't carry the augmentation risk of dopaminergic drugs. Side effects include sedation, dizziness, and weight gain. A specific extended-release gabapentin formulation (Horizant/gabapentin enacarbil) is FDA-approved specifically for RLS.

Dopamine Agonists

Pramipexole (Mirapex) and ropinirole (Requip) are approved for RLS and were previously first-line. They remain effective but carry a significant long-term risk called augmentation.

Augmentation โ€” the most important risk of dopamine agonists for RLS: Augmentation is a paradoxical worsening of RLS that occurs with long-term dopamine agonist use. Symptoms begin earlier in the day, become more intense, spread to the arms and trunk, and require increasing doses. It affects 30โ€“70% of patients on long-term dopamine agonist therapy and can be more disabling than the original RLS. For this reason, alpha-2-delta ligands are now preferred for most patients, and dopamine agonists are used at the lowest effective dose or avoided for long-term use in many guidelines.

Low-Dose Opioids

Low-dose opioids (methadone, oxycodone, buprenorphine) are sometimes used for severe, refractory RLS unresponsive to other treatments. Effective but carries addiction potential and requires specialist management.

When to Seek Help

  • Symptoms occur 3+ times per week and significantly impair sleep or quality of life
  • Symptoms are worsening despite lifestyle modifications
  • You want a ferritin test to check for iron deficiency
  • You're pregnant and developing RLS symptoms
  • You're taking a medication that may be contributing

Frequently Asked Questions

Is RLS the same as "growing pains"?
Possibly related. "Growing pains" in children โ€” uncomfortable leg sensations at night that are relieved by movement and massage โ€” often meet criteria for pediatric RLS. The condition is underdiagnosed in children and can significantly disrupt sleep. If a child has recurring nighttime leg discomfort that follows the RLS pattern (worse at rest, worse at night, relieved by movement), a pediatrician should evaluate for RLS and check ferritin levels.
Why is ferritin more important than hemoglobin for RLS?
Hemoglobin reflects circulating iron in red blood cells. Ferritin reflects iron stores throughout the body, including in the brain. The brain can become iron-deficient (specifically in dopaminergic regions relevant to RLS) before hemoglobin falls to anemic levels. Many RLS patients have normal hemoglobin โ€” they're not anemic in the traditional sense โ€” but have suboptimal brain iron that compromises dopamine function. Only ferritin captures this.
Can RLS affect the arms?
Yes, though less commonly. The condition most commonly affects the legs but can involve the arms in approximately 30โ€“50% of patients, particularly those with more severe disease or augmentation from dopamine agonist use. Augmentation (worsening from dopamine agonist treatment) specifically tends to spread symptoms from legs to arms and trunk.
Does RLS go away on its own?
RLS associated with a secondary cause (iron deficiency, pregnancy, medication) often improves significantly or resolves when the underlying cause is addressed. Primary (idiopathic) RLS typically persists long-term, though symptom severity can fluctuate. For many patients, symptoms wax and wane โ€” good periods alternating with worse periods โ€” without complete resolution. Effective management rather than cure is the realistic expectation for primary RLS.
Is there a connection between RLS and Parkinson's disease?
There is a mechanistic overlap โ€” both involve dopamine system dysfunction โ€” and RLS patients have slightly elevated rates of Parkinson's disease compared to the general population. However, the vast majority of RLS patients do not develop Parkinson's disease, and RLS is not considered a prodromal syndrome for Parkinson's in the way that REM behavior disorder is. The shared dopaminergic pathways explain why dopamine agonists (which are also used in Parkinson's) treat RLS.